Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058910 · ClinicalTrials.gov registry record
Bilistick Point-of-care System 2.0 Bilirubin Validation
A clinical trial, sponsored by Kettering Health Network.
- Completed
- Registry status
- 80
- Enrollment target
NCT06058910: Completed study, sponsored by Kettering Health Network.
NCT06058910 is a clinical trial that has completed, run by Kettering Health Network. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06058910 has completed, sponsored by Kettering Health Network.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
Study Summary
This is a validation study involving the Bilistick System 2.0 point-of-care bilirubin measuring device. The validation will be conducted by comparing bilirubin measurements utilizing the standard-of-care blood sample collected for both a diagnostic reference device and Bilistick System 2.0 point-of-care device. Whole blood samples collected from male or female newborns (\<2-weeks of age) born at a Kettering Health Network facility to obtain a total of 80 valid comparison pairs between the reference device and the Bilistick System 2.0 point-of-care device with current laboratory standards.
Primary Outcome
Measurement of total bilirubin (milligram/deciliter) using the Bilistick 2.0 point-of-care system
Interventions
- DIAGNOSTIC_TEST Bilistick System 2.0 point-of-care testing device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2024-09-09 |
What the finished NCT06058910 record still lists
NCT06058910 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Bilistick System 2.0 point-of-care testing device is the first listed.
NCT06058910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06058910 about?
NCT06058910 is a clinical study titled "Bilistick Point-of-care System 2.0 Bilirubin Validation". This is a validation study involving the Bilistick System 2.0 point-of-care bilirubin measuring device. The validation will be conducted by comparing bilirubin measurements utilizing the standard-of-care blood sample collected for both a diagnostic reference device and Bilistick System 2.0 point-of-...
What is the current status of trial NCT06058910?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2024-02-01. Estimated completion is 2024-09-09.
What interventions are being tested in trial NCT06058910?
The interventions under investigation include: Bilistick System 2.0 point-of-care testing device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06058910?
This trial is sponsored by Kettering Health Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI